Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Elevating Autoimmune Disease Market Understanding with DLI's Research Expertise | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

10 Oct, 2023, 07:04 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 10, 2023 /PRNewswire/ -- The increase autoimmune disease burden has become a cause of global health concern.  As per an autoimmune disease epidemiology study conducted by the National Institute of Environmental Health Sciences, more than 24 million people are diagnosed with autoimmune disorders in the US alone.  This alarming statistic has created an immediate requirement for the conduction of proper R&D activities in the field so as to cater to autoimmune disease unmet needs.

Autoimmune diseases and disorders are a group of conditions in which the body's immune system mistakenly attacks its own tissues and organs. There are over 100 different autoimmune diseases, and they can affect any part of the body. The pervasiveness of autoimmune disorders can vary significantly depending on the specific condition and the population being studied. Early diagnosis is the key to the proper management of such disorders.

Disease Landscape Insights has been offering healthcare consulting services to the players operating in this vertical. From drug development, clinical trial management, and treatment gaps identification to the formulation of drug launch strategies, DLI has been assisting them through all such complicated phases.

DLI's exhaustive approach to autoimmune disease research covers below and many other cancer types. DLI is aiding research and care for each of these specific disease categories-

  • Crohn's Disease
  • Celiac Disease
  • Dermatomyositis
  • Psoriasis Disease
  • Addison Disease
  • Myasthenia Gravis
  • Graves Disease
  • Multiple Sclerosis
  • Hashimoto Thyroiditis
  • Others

Price and Market Access

Shedding light on the characteristics and symptoms of such disorders

There are a wide range of autoimmune disorders with distinct characteristics, traits, and symptoms. But most of these diseases are chronic in nature and do not have a permanent cure. Some of the commonly occurring symptoms of these ailments are inflammation, fatigue, pain, along with the occurrence of other comorbidities. It is also worth noting that some individuals may develop multiple autoimmune ailments at once that can affect multiple organs of the body.

Environmental factors, such as infections, stress, and hormonal changes, can trigger or exacerbate autoimmune diseases in susceptible individuals. Such diseases can significantly impact a person's quality of life, leading to disability, reduced mobility, and emotional distress.

Diagnostic Landscape:

In the diagnostic landscape of autoimmune disorders, healthcare professionals employ various methods to identify and confirm these conditions. One critical approach involves the detection of specific autoantibodies in blood tests. Imaging techniques, such as MRI, CT scans, and ultrasound, play a vital role in visualizing affected organs and tissues. In some cases, healthcare providers may recommend tissue biopsies, such as skin, joint, or organ biopsies, to confirm a diagnosis and evaluate tissue damage. Furthermore, genetic testing is becoming increasingly important, as it helps identify genetic markers and susceptibility genes associated with various autoimmune diseases.

Treatment Landscape:

The treatment landscape of autoimmune disorders is multifaceted and often involves medications and therapies aimed at managing symptoms and modulating the immune system. Immunosuppressants like corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are commonly used to suppress the overactive immune response and reduce inflammation. Biologic therapies, another crucial category of drugs, target specific molecules involved in the immune response. Monoclonal antibodies have gained prominence for their ability to block immune responses or modulate particular pathways implicated in autoimmune diseases. Pain management is an integral part of treatment, with analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) providing relief from pain and discomfort associated with autoimmune disorders. Physical therapy and rehabilitation programs are often recommended to improve joint and muscle function in conditions like rheumatoid arthritis.

Autoimmune Disease Pipeline:

The autoimmune disease pipeline is characterized by ongoing research and clinical trials that aim to develop new autoimmune diseases medications and therapies. These trials evaluate the safety and efficacy of innovative treatments for autoimmune diseases. Collaboration between biopharmaceutical companies and research institutions plays a vital role in advancing the field. The focus is on targeted therapies that address specific aspects of autoimmune diseases, aiming for greater precision and effectiveness. DLI has been aiding in autoimmune disorder drug management, helping autoimmune disease market players with price and market access, product portfolio extension, adherence to regulatory standards, while offering them with post launch services. 

Pfizer inflammation and immunology Pipeline

The repository of Pfizer inflammation and immunology products is vast. This pharma company has emerged as a global leader in the autoimmune disease treatment landscape. It has developed various drugs and therapies to treat such disorders and manage primary symptoms like inflammation. Enbrel, rapamune, bosulif, eucrisa, xeljanz, and ibrance, among others are some of the major drugs introduced by Pfizer.

Pharma consulting Services

Summing Up

Autoimmune disease statistics 2023 conducted by well-known research organizations point towards an alarming increase in the prevalence of such disorders.  These ailments are caused when immune system mistakenly targets the body's own healthy cells and tissues. These disorders are characterized by chronic inflammation, multi-organ involvement, and a wide range of symptoms that can significantly impact an individual's quality of life. DLI encompasses a comprehensive understanding of the current state of autoimmune diseases, including their epidemiology, genetics, diagnostic approaches, and available treatments. These insights play a pivotal role in assisting various stakeholders, including healthcare providers, pharmaceutical companies, researchers, and policymakers.

About Disease Landscape: 

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to the healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us: 
Disease Landscape Insights LLP 
6th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar 
Pune, Maharashtra, 411014 
Email: ajay@diseaselandscape.com   
Email: vishal@diseaselandscape.com
Sales: +44-2038074155 
Asia Office: +917447409162
Blog: https://www.diseaselandscape.com/blogs 
Case Study: https://www.diseaselandscape.com/casestudies  
Pharma consulting Services 
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.